Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390342 | 0.90 | CHRM2 (0.54) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL25616626 | 0.87 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL20328930 | 0.87 | CHRM2 (0.55) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL25010681 | 0.82 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2123260 | 0.82 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL24726807 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL8374380 | 0.81 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL27457738 | 0.81 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL12425806 | 0.81 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL26361913 | 0.81 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| US-9127013-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8865698-B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130217662-A1 | METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2013-08-22 | — | — | US | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | CHRM2 1570/4885CHRM1 1507/4885CHRM3 1618/4885 |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CHRM2 92/4885CHRM1 123/4885CHRM3 180/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | CHRM2 1738/4885CHRM1 1677/4885CHRM3 1543/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CHRM2 730/4885CHRM1 1155/4885CHRM3 2269/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | CHRM2 1178/4885CHRM1 483/4885CHRM3 596/4885 |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | TYMP, TYMS, P2RX7 | CHRM2 1013/4885CHRM1 322/4885CHRM3 498/4885 |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CHRM2 90/4885CHRM1 121/4885CHRM3 181/4885 |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRM2 1013/4885CHRM1 322/4885CHRM3 498/4885 |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | P2RX7, P2RX1, P2RX3 | CHRM2 62/4885CHRM1 23/4885CHRM3 106/4885 |
| US-20130217662-A1 | METHOD OF TREATMENT USING SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS | COL2A1, COL1A1, IFNAR1 | CHRM2 33/4885CHRM1 14/4885CHRM3 221/4885 |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRM2 1013/4885CHRM1 322/4885CHRM3 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.